glp-1 receptor agonists in idiopathic intracranial hypertension The effect of glucagon-like peptide-1 on ocular parameters patients: a retrospective study A glucagon-like peptide-1 receptor agonist
Description
(2025, February 1)
Hale, P
Nunn said Rhode Island should form purchasing partnerships with bigger states like Massachusetts or California to get better prices from the pharmaceutical industry
They were also randomly assigned to receive once-weekly injections of placebo, 1.5 mg dulaglutide, or retatrutide maintenance doses of 0.5 mg, 4 mg (starting dose 2 mg), 4 mg (no escalation), 8 mg (starting dose 2 mg), 8 mg (starting dose 4 mg), or 12 mg (starting dose 2 mg)
J., Krahn, D
